Array BioPharma inks deal with Biogen Idec on autoimmune disorders

30 May 2014
2019_biotech_test_vial_discovery_big

US biotech firms Array BioPharma (Nasdaq: ARRY) and Biogen Idec (Nasdaq: BIIB) have entered into a collaboration for the discovery and development of inhibitors targeting a novel kinase for the treatment of autoimmune disorders.

Under the terms of the accord, Biogen and Array will collaborate on the discovery of the novel kinase inhibitors. Biogen will be responsible for all aspects of clinical development and commercialization. The agreement includes research funding for three years, various milestone payments payable upon achievement of certain development and commercial milestones, and royalties to Array. Further financial terms were not disclosed. Nevertheless, Array’s shares rose 6.2% to $4.36 on the news.

Will use Array’s Kinase-Directed Phenotypic Screening Platform

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology